Top

Published in:

01-07-2014 | Original Article

Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients

Authors: Juan Antonio Cruzado, Sonia López-Santiago, Virginia Martínez-Marín, Gema José-Moreno, Ana Belén Custodio, Jaime Feliu

Published in: Supportive Care in Cancer | Issue 7/2014

Abstract

Background

Chemotherapy can induce cognitive impairment in cancer patients. The main goal of this longitudinal study was to determine the incidence, characteristics, and duration of cognitive dysfunction in patients treated with adjuvant chemotherapy for colon cancer.

Patients and methods

We assessed cognitive function, quality of life, anxiety and depression, fatigue, and hemoglobin levels in colon cancer patients at three assessment points: pre-chemotherapy (n = 81), post-chemotherapy (n = 73), and after 6-month follow-up (n = 54). All patients were treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) for 6 months.

Results

Thirty patients (37 %) had cognitive impairment in the pre-chemotherapy evaluation, mainly in processing speed and psychomotor executive function (Trail Making Test A and B). At the end of treatment, the main domain affected was the verbal memory, with an acute decline detected in 56 % of patients. Fifty-four percent of the patients improved their dysfunction after 6 months of follow-up, whereas 18 (33 %) of them showed worsening in at least one test. Cognitive impairment was most common in older patients and in those with less years of education. Quality of life, anxiety, depression, fatigue, and hemoglobin did not influence the results of the cognitive tests.

Conclusions

Adjuvant FOLFOX4 in patients with colon cancer can have a negative effect on verbal memory. This deterioration is usually mild and transient.

Argyriou AA, Assimakopoulos K, Iconomou G et al (2011) Either called “chemobrain” or “chemofog”, the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage 41:126–139. doi:10.1016/j.jpainsymman.2010.04.021 CrossRef

Janelsins MC, Kohli S, Mohile SG et al (2011) An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 20(38):431–438. doi:10.1053/j.seminoncol.2011.03.014 CrossRef

Ahles TA, Saykin AJ, Furstenberg CT et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493. doi:10.1200/JCO.20.2.485 PubMedCrossRef

Wefel JS, Lenzi R, Theriault RL et al (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299. doi:10.1002/cncr.20272 PubMedCrossRef

Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116:113–123. doi:10.1007/s10549-008-0211-2 PubMedCrossRef

Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348–3356. doi:10.1002/cncr.25098 PubMedCrossRef

Phillips KM, Jim HS, Small BJ et al (2012) Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer 118:1925–1932. doi:10.1002/cncr.26432 PubMedCentralPubMedCrossRef

Koppelmans V, Breteler MM, Boogerd W et al (2012) Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 30:1080–1086. doi:10.1200/JCO.2011.37.0189 PubMedCrossRef

Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25:2455–2463. doi:10.1200/JCO.2006.08.1604 PubMedCrossRef

10.

Wefel JS, Schagen SB (2012) Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 12:267–275. doi:10.1007/s11910-012-0264-9 PubMedCrossRef

11.

Jansen CE, Miaskowski C, Dodd M et al (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104:2222–2223. doi:10.1002/cncr.21469 PubMedCrossRef

12.

Falleti MG, Sanfilippo A, Maruff P et al (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59:60–70. doi:10.1016/j.bandc.2005.05.001 PubMedCrossRef

13.

Stewart A, Bielajew C, Collins B et al (2006) (2006). A metaanalysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 20:76–89. doi:10.1080/138540491005875 PubMedCrossRef

14.

Jim HS, Phillips KM, Chait S et al (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578–3587. doi:10.1200/JCO.2011.39.5640 PubMedCentralPubMedCrossRef

15.

Boykoff N, Moieni M, Subramanian SK (2009) (2009). Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3:223–232. doi:10.1007/s11764-009-0098-x PubMedCentralPubMedCrossRef

16.

Ahles TA, Saykin AJ, McDonald BC et al (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440. doi:10.1200/JCO.2009.27.0827 PubMedCentralPubMedCrossRef

17.

Schagen SB, Muller MJ, Boogerd W et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387–1397. doi:10.1093/annonc/mdf241 PubMedCrossRef

18.

Vearncombe KJ, Rolfe M, Wright M et al (2009) Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 15:951–962. doi:10.1017/S1355617709990567 PubMed

19.

Jenkins V, Shilling V, Deutsch G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834. doi:10.1038/sj.bjc.6603029 PubMedCentralPubMedCrossRef

20.

Hermelink K, Untch M, Lux MP et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109:1905–1913. doi:10.1002/cncr.22610 PubMedCrossRef

21.

Jim HS, Donovan KA, Small BJ et al (2009) Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115:776–783. doi:10.1002/cncr.24192 CrossRef

22.

Wefel J, Vardy J, Ahles T, Schagen S (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708. doi:10.1016/S1470-2045(10)70294-1 PubMedCrossRef

23.

Peña-Casanova J (2005) Test de Barcelona-Revisado. Programa Integrado de Exploración Neuropsicológica. Elsevier- Masson, Barcelona

24.

Reitan RM, Olfson D (1985) The Halstead–Reitan Neuropsychological Test Battery: therapy and clinical interpretation. Neuropsychological Press, Tucson

25.

Tombaugh TN (2004) Trail making test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19:203–214. doi:10.1016/S0887-6177(03)00039-8

26.

Wechsler D (2001) Escala de Inteligencia para adultos, 3ª versión. TEA, Madrid

27.

Golden CJ (2005) Stroop, Test de Colores y Palabras. TEA, Madrid

28.

Fayers P, Bottomley A, EORTC Quality of Life Group; Quality of Life Unit (2002) Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38(Suppl 4):S125–S133. doi:10.1016/S0959-8049(01)00448-8 PubMedCrossRef

29.

Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370. doi:10.1111/j.1600-0447.1983.tb09716.x PubMedCrossRef

30.

Mendoza TR, Wang XS, Cleeland CS et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85:1186–1196. doi:10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N PubMedCrossRef

31.

Crawford JR, Garthwaite PH, Gault CB (2007) Estimating the percentage of the population with abnormally low scores (or abnormally large score differences) on standardized neuropsychological test batteries: a generic method with applications. Neuropsychology 21:419–430. doi:10.1037/0894-4105.21.4.419 PubMedCrossRef

32.

Chelune GJ, Naugle RI, Luders H et al (1993) Individual change after epilepsy surgery: practice effects and base-rate information. Neuropsychology 7:41–52. doi:10.1037//0894-4105.7.1.41 CrossRef

33.

Quintana M, Peña-Casanova J, Sánchez-Benavides G et al (2011) Spanish multicenter normative studies (Neuronorma project): norms for the abbreviated Barcelona test. Arch Clin Neuropsychol 26:144–157. doi:10.1093/arclin/acq098 PubMedCrossRef

34.

García A, Fernández M, Blesa R et al (2012) Using artificial neural networks in clinical neuropsychology: high performance in mild cognitive impairment and Alzheimer’s disease. Exp Neuropsychol 34:195–208. doi:10.1080/13803395.2011.630651 CrossRef

35.

Molinuevo JL, Gómez-Anson B, Monte GC et al (2011) Neuropsychological profile of prodromal Alzheimer’s disease (Prd-AD) and their radiological correlates. Arch Gerontol Geriatr 52:190–196. doi:10.1016/j.archger.2010.03.016 PubMedCrossRef

36.

Lezak MD, Howieson DB, Bigler ED et al (2012) Neuropsychological assessment, 5th edn. Oxford University Press, New York

37.

Vardy JL, Dhillon H, Xu W, et al. (2009). Cognitive function and fatigue in colorectal cancer (CRC) patients: baseline assessments prior to chemotherapy. J Clin Oncol 27:15 s (Suppl; abstract 9557).

38.

Wefel JS, Vidrine DJ, Veramonti TL et al (2011) Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 117:190–196. doi:10.1002/cncr.25298 PubMedCrossRef

39.

Benveniste H, Zhang S, Reinsel RA et al (2012) (2012). Brain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopy. Int J Clin Exp Med 5:154–164PubMedCentralPubMed

40.

Andreis F, Ferri M, Mazzocchi M et al (2013) (2013). Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study. Support Care Cancer 21:583–590. doi:10.1007/s00520-012-1560-2 PubMedCrossRef

41.

Mancuso A, Migliorino M, De Santis S et al (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17:146–150. doi:10.1093/annonc/mdj038 PubMedCrossRef

42.

Hang R, Yang YM, Dietrich J et al (2008) Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7:12. doi:10.1186/jbiol69 CrossRef

43.

Sharpe MJ, Fardell JE, Vardy J, Johnston IN (2012) The chemotherapy agent oxaliplatin impairs the renewal of fear to an extinguished conditioned stimulus in rats. Behav Brain Res 227:295–299. doi:10.1016/j.bbr.2011.11.005 PubMedCrossRef

44.

Fardell JE, Vardy J, Shah JD, Johnston IN (2012) Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychophar-macology (Berl) 220:183–193. doi:10.1007/s00213-011-2466-2

Title: Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients
Authors: Juan Antonio Cruzado
Sonia López-Santiago
Virginia Martínez-Marín
Gema José-Moreno
Ana Belén Custodio
Jaime Feliu
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 7/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2147-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2014

Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen

A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic

Exercise training in patients with advanced gastrointestinal cancer undergoing palliative chemotherapy: a pilot study

Is breathlessness what the professional says it is? Analysis of patient and professionals’ assessments from a German nationwide register

Quality of dying and death with cancer in Israel

Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey

Keynote webinar | Spotlight on antibody–drug conjugates in cancer